MDMB-BINACA (MDMB-BUTINACA) is an

indazole Indazole, also called isoindazole, is a heterocyclic aromatic organic compound. This bicyclic compound consists of the fusion of benzene and pyrazole. Indazole is an amphoteric molecule which can be protonated to an indazolium cation or deprotona ...

-3-carboxamide based

synthetic cannabinoid Synthetic cannabinoids, or neocannabinoids, are a class of designer drug molecules that Binding affinity, bind to the same receptors to which cannabinoids (Tetrahydrocannabinol, THC, Cannabidiol, CBD and many others) in cannabis plants attach. Th ...

receptor agonist that has been sold as a

designer drug A designer drug is a structural or functional analog of a controlled substance that has been designed to mimic the pharmacological effects of the original drug, while avoiding classification as illegal and/or detection in standard drug tests. ...

, first identified in Sweden in May 2023. It has a similar chemical structure to potent cannabinoid agonists previously reported such as

ADB-BUTINACA ADB-BUTINACA (also known as ADMB-BINACA using EMCDDA naming standards) is a synthetic cannabinoid compound which has been sold as a designer drug. It is a potent CB1 agonist, with a binding affinity of 0.29nM for CB1 and 0.91nM for CB2, and an E ...

and

MDMB-5'Br-BUTINACA MDMB-5'Br-BUTINACA (5'-Br-MDMB-BUTINACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist that has been sold as a designer drug. It was first identified in Russia in August 2022. It is believed to be synthesized from the ...

, and is believed to have similar effects.

References

Cannabinoids Designer drugs Amides Tert-butyl compounds Indazolecarboxamides Methyl esters {{cannabinoid-stub

See also

References